Long-term Side Effects of Flunarizine
Flunarizine's most concerning long-term side effects are weight gain (occurring in approximately 54% of patients), depression (particularly in elderly patients), and extrapyramidal symptoms including parkinsonism, which can be persistent even after drug discontinuation.
Primary Long-term Adverse Effects
Weight Gain and Sedation
The most common long-term side effects are:
- Weight gain: Occurs in approximately 54% of patients, with mean increases of 7.9 ± 6.9 kg over 24 months 1
- Sedation/drowsiness: Affects 42% of patients, typically most prominent within the first month 1
- These effects are dose-dependent and more pronounced at the standard 10 mg daily dose 2, 3
Neuropsychiatric Effects
Depression is a critical concern that warrants close monitoring:
- Retarded-type depression is the most frequent cause requiring treatment discontinuation (7.5% of patients) 1
- Depression risk is particularly elevated in elderly patients 3
- This is significant enough that depression is listed as a contraindication to flunarizine use 2
Movement Disorders (Most Serious Long-term Complication)
Extrapyramidal symptoms, particularly parkinsonism, represent the most serious long-term risk:
- Occurs predominantly in elderly patients (>60 years), even at recommended doses of 10 mg daily 4
- In a series of 101 patients (mean age 69.1 years), movement disorders developed that closely resembled neuroleptic-induced symptoms 5
- Critical distinction in recovery patterns 4:
- 74% (20/27 patients) showed complete recovery within 6 months of discontinuation
- 26% (7/27 patients) showed persistent parkinsonism requiring L-dopa treatment for 12-24 months despite drug withdrawal
The persistence of symptoms 2 months after discontinuation indicates likely permanent changes requiring antiparkinson medication 4.
Mechanism and Risk Factors
These side effects are attributed to:
- Dopamine receptor blockade (causing parkinsonism and depression)
- Calcium channel antagonism
- Age >60 years is the primary risk factor for irreversible movement disorders 5, 4
Clinical Implications
Monitoring Requirements
- Regular assessment for mood changes and depression
- Weight monitoring throughout treatment
- In elderly patients: Specific evaluation for bradykinesia and parkinsonian features using ballistic movement testing 4
- If parkinsonian symptoms persist 2 months after discontinuation, initiate antiparkinson therapy 4
Duration Considerations
- Long-term treatment should be discouraged, particularly in elderly patients 5
- In responders, 64% continued treatment for >1 year, suggesting tolerability in selected patients 6
- Guidelines recommend the smallest effective dose for the shortest duration 3
Pediatric Population
In children, the side effect profile is somewhat different:
- Adverse effects occur in 21% (depression 8%, weight gain 7%, tiredness 3%) 7
- Discontinuation rate due to side effects: 18% 7
- Generally better tolerated than in adults
Contraindications Based on Long-term Risks
Absolute contraindications 2:
- Pre-existing parkinsonism
- Depression
- Elderly patients should be prescribed with extreme caution given irreversible parkinsonism risk
The evidence strongly suggests that while flunarizine is effective for migraine prophylaxis, its long-term use requires careful patient selection, avoiding elderly patients and those with mood disorders, with vigilant monitoring for weight gain, depression, and movement disorders throughout treatment.